The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, the gravity of unmet medical needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Environmental Sustainability in Pharmaceuticals: Anti-malarial peptides

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. 

Anti-malarial peptides is a key innovation area in environmental sustainability 

Anti-malarial peptides exhibit activity on malaria parasites, Plasmodium spp., either in blood or mosquito stages, or both. The range of natural and synthetic molecules that make up these peptides is broad, with differences in size, charge, hydrophobicity, and secondary structural characteristics. The activity of anti-malarial peptides is influenced by several environmental variables, including pH, metal ions, and proteases. 

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-malarial peptides. 

Key players in anti-malarial peptides– a disruptive innovation in the pharmaceutical industry  

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators. 

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’. 

Patent volumes related to anti-malarial peptides

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
GSK 121 Unlock company profile
U.S. Department of Defense 52 Unlock company profile
Inovio Pharmaceuticals 39 Unlock company profile
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung 34 Unlock company profile
Centre National de la Recherche Scientifique 28 Unlock company profile
Zydus Lifesciences 28 Unlock company profile
SuZhou SJ Biomaterials 28 Unlock company profile
United States Of America 24 Unlock company profile
VLP Therapeutics 24 Unlock company profile
Ligand Pharmaceuticals 24 Unlock company profile
Johnson & Johnson 22 Unlock company profile
Abbott Laboratories 20 Unlock company profile
Otsuka Holdings 17 Unlock company profile
CAS-Lamvac Biotech 16 Unlock company profile
Institut Pasteur 16 Unlock company profile
United Biomedical 14 Unlock company profile
Seattle Children's Hospital 10 Unlock company profile
Statens Serum Institut 10 Unlock company profile
Theravectys 10 Unlock company profile
Rhode Island Hospital 9 Unlock company profile
Vac-4-All 9 Unlock company profile
Edwards Lifesciences 8 Unlock company profile
Fundacio Cellex 8 Unlock company profile
Hospital for Sick Children 7 Unlock company profile
Sumitomo Chemical 7 Unlock company profile
Eisai 7 Unlock company profile
Oxford BioMedica 7 Unlock company profile
Hawaii Biotech 7 Unlock company profile
US Government 6 Unlock company profile
Catalan Institution for Research and Advanced Studies 6 Unlock company profile
IMV 5 Unlock company profile
Henry M. Jackson Foundation for the Advancement of Military Medicine 5 Unlock company profile
US Department of Health and Human Services 5 Unlock company profile
Centre de Recerca en Salut Internacional de Barcelona 5 Unlock company profile
Sumaya Biotech 5 Unlock company profile

Source: GlobalData Patent Analytics

GSK is a leading healthcare company that focuses on developing, manufacturing and commercialising pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterial, dermatological, and certain rare diseases. GSK and Medicines for Malaria Venture (MMV) together have developed a preclinical portfolio of antimalarial properties. Through its extensive global R&D and supply network, GSK offers clinical, regulatory, and manufacturing knowledge and resources when compounds enter the clinical development stage. In 2021, the WHO recommended broader use of GSK’s Mosquirix to reduce illness and deaths from malaria in children living in sub-Saharan Africa and other regions with moderate to high transmission as defined by the WHO. 

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.